ClinicalTrials.gg
RecruitingNCT07100119Updated Nov 5, 2026

A Study of LY4256984 in Participants With Sporadic Amyotrophic Lateral Sclerosis

A Phase 1 interventional study of LY4256984 and Placebo in ALS (Amyotrophic Lateral Sclerosis), sponsored by Eli Lilly and Company. Recruiting at 12 sites in 5 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.
Updated Nov 5, 2026Site recruiting status changedEnrollment updated+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.

Planned enrollment
52nd of 72
36 · median 75
Started
2025
with 4 others
Phase 1
16 of 82
5 open now
Primary completion
2027-08
later than 13 of 24 live
Registered
76th of 82
by date
Lead sponsor
4 of 82
Eli Lilly and Company

Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 52nd largest by planned enrollment of the 72 interventional ones that give a count, is one of 5 that started in 2025, is one of 16 in phase 1, reaches primary completion later than 13 of the 24 other live ones, and was the 76th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate how well LY4256984 is tolerated and what side effects may occur in participants with sporadic amyotrophic lateral sclerosis (ALS). The study drug will be administered intrathecally (IT) into the spine. Blood tests will be performed to check how much LY4256984 gets into the bloodstream and how long it takes the body to eliminate it.

03

Conditions studied

  • ALS (Amyotrophic Lateral Sclerosis)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a definite, possible, or probable diagnosis of sporadic amyotrophic lateral sclerosis (ALS) made by a physician experienced with the management of ALS
  • ALS symptom onset as determined by the Investigator within 24 months of Screening
  • Have a (BMI) within the range of greater than or equal to 18.0 and less than or equal to 35.0 kilogram per square meter (kg/m²) (inclusive)

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of medical illness including, but not limited to, any cardiovascular, renal, hepatic, gastrointestinal, respiratory, hematological, endocrine, psychiatric, or neurological disease, convulsions, or any laboratory abnormality
  • Have a history of another neurodegenerative disease or significant dementia/severe cognitive problems
  • Have serum (ALT), aspartate transferase (AST), or total levels greater than 2 x .
  • Have a significant renal impairment (estimated \<60 milliliters per minute [mL/min]/1.73 m²).
  • Have a 12-lead (ECG) abnormality at screening, in the opinion of the investigator, that increases the risks associated with participating in the study
  • Show clinically significant abnormalities in lumbar spine previously known or determined by screening lumbar X-ray or fluoroscopy (if performed)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    LY4256984 (Cohorts 1-3)

    Multiple ascending doses (MAD) of LY4256984 administered intrathecally (IT)

    Drug: LY4256984

  • Placebo comparator
    Placebo

    Administered IT

    Drug: Placebo

Interventions

  • Administered IT

  • DrugPlacebo

    Administered IT

06

What researchers measure

Primary outcomes

  1. Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs), Serious Adverse Event(s) (SAEs), and Adverse Event(s) (AEs) Considered by the Investigator to be Related to Study Drug Administration

    A summary of TEAEs, SAEs, and AEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline up to Approximately Day 253

Secondary outcomes

  1. Pharmacokinetics (PK): Plasma Area Under the Concentration Versus Time Curve (AUC) of LY4256984

    PK: Plasma AUC of LY4256984

    Time frame: Baseline up to Approximately Day 253

  2. PK: Plasma Maximum Concentration (Cmax) of LY4256984

    PK: Plasma Cmax of LY4256984

    Time frame: Baseline up to Approximately Day 253

  3. PK: Cerebrospinal Fluid Concentrations (CSF) of LY4256984

    PK: CSF Concentrations of LY4256984

    Time frame: Baseline up to Approximately Day 253

07

Study locations

10 of 12 sites recruiting
  • UZ Leuven
    Leuven, 3000, Belgium
    Recruiting
    • · Contact(321) 634-4280
    • Philip Van Damme · Principal investigator
  • Heritage Medical Research Clinic
    Calgary, T2N4Z6, Canada
    Recruiting
    • · Contact403-210-7006
    • Theodore Mobach · Principal investigator
  • Walter Mackenzie Health Sciences Centre
    Edmonton, T6G 2X8, Canada
    Not yet recruiting
    • · Contact780.248.1089
    • Peter Dobrowolski · Principal investigator
  • London Health Sciences Centre
    London, N6A 5A5, Canada
    Recruiting
    • · Contact519-663-3597
    • Christen Shoesmith · Principal investigator
  • Montreal Neurological Institute and Hospital
    Montreal, H3A 2B4, Canada
    Recruiting
    • · Contact514-449-8741
    • Angela Genge · Principal investigator
  • Sunnybrook Research Institute
    Toronto, M4N 3M5, Canada
    Recruiting
    • · Contact4134806860
    • Agessandro Abrahao · Principal investigator
  • Universitätsklinikum Schleswig-Holstein
    Lübeck, 23538, Germany
    Recruiting
    • · Contact4936419323426
    • Julian Grosskreutz · Principal investigator
  • Universitätsmedizin Rostock Sektion für Translationale Neurodegeneration "Albrecht Kossel" Klinik und Poliklinik für Neurologie
    Rostock, 18147, Germany
    Not yet recruiting
    • · Contact49 (0)381 494-9541
    • Andreas Hermann · Principal investigator
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
    Recruiting
    • · Contact(497315) 006-3099
    • Jochen Weishaupt · Principal investigator
  • Universitair Medisch Centrum Utrecht
    Utrecht, 3584, Netherlands
    Recruiting
    • · Contact31887553204
    • Leonard van den Berg · Principal investigator
  • Hospital Universitario de Bellvitge
    L'Hospitalet de Llobregat, 8907, Spain
    Recruiting
    • · Contact+34 933359011 ext 8486
    • Monica Povedano · Principal investigator
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
    Recruiting
    • · Contact34644490025
    • Juan Francisco Vazquez Costa · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2027, 24 months after the start.

Of 40 industry-sponsored phase 1 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 38. This study's planned 24 months is above that.

Counting every sponsor, half of 70 studies reached it within 21 months; a quarter within 13 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 31, 2025
First posted
Aug 3, 2025
StartActual
Aug 5, 2025
Primary completionEst.
Aug 2027
CompletionEst.
Sep 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Heritage Medical Research Clinic · Calgary, CanadaNot yet recruiting→Recruiting
  • London Health Sciences Centre · London, CanadaNot yet recruiting→Recruiting
  • Universitätsklinikum Ulm · Ulm, GermanyNot yet recruiting→Recruiting
Nov 5, 2026
Enrollment
32→36
Nov 5, 2026
Interventions
Arm changed LY4256984 (Cohorts 1-4)→LY4256984 (Cohorts 1-3)
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    3 sites changed recruiting status (3 now recruiting)
    Show 3 sites
    • Heritage Medical Research Clinic · Calgary, CanadaNot yet recruiting→Recruiting
    • London Health Sciences Centre · London, CanadaNot yet recruiting→Recruiting
    • Universitätsklinikum Ulm · Ulm, GermanyNot yet recruiting→Recruiting
    Enrollment 32→36
    Interventions Arm changed LY4256984 (Cohorts 1-4)→LY4256984 (Cohorts 1-3)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07100119
Responsible party
Sponsor
First posted
Aug 3, 2025
Start date
Aug 5, 2025
Primary completion
Aug 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Contact
LillyTrials@Lilly.com
1-317-615-4559
Physicians interested in becoming principal investigators please contact
Contact
clinical_inquiry_hub@lilly.com
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY4256984

Start the discussion